法国九价性别中性HPV疫苗接种规划的公共卫生影响与成本效果
研究用已发表的HPV疾病传播动态模型,校准至法国数据,评估九价性别中性接种(GNV)与仅女孩接种(GOV)相比的公共卫生影响与成本效果。结果显示GNV在100年内额外减少宫颈癌、肛门癌病例与死亡及生殖器疣,ICER为24,763€/QALY(基础案例),结论认为GNV具有显著公共卫生效益且可能具成本效果。
要点
- GNV较GOV额外减少宫颈癌、肛门癌病例与死亡及生殖器疣。
- 基础案例ICER为24,763€/QALY,纳入所有HPV相关疾病时为15,184€/QALY。
- 高覆盖率(60%)下GNV仍可额外预防癌症病例与死亡及生殖器疣。
核心结论
- 在法国,九价性别中性HPV疫苗接种规划具有显著公共卫生效益,与仅女孩接种相比在低和高覆盖率下均可能具成本效果。
研究设计与样本
- 采用已发表的HPV疾病传播动态模型,考虑群体保护效应,时间跨度100年,校准至法国数据。
- 比较九价性别中性接种(GNV)与仅女孩接种(GOV)两种策略。
- GNV规划假设女孩和男孩覆盖率均为26.2%,基于法国当前女性覆盖率。
- 基础案例包括生殖器疣、宫颈癌、外阴癌、阴道癌和肛门癌。
主要发现
- 100年内,GNV较当前GOV额外减少9,519例宫颈癌病例和3,037例宫颈癌死亡。
- GNV额外减少6,901例肛门癌病例和1,166例肛门癌死亡。
- GNV额外减少1,284,077例生殖器疣。
- 基础案例ICER为24,763€/QALY;纳入所有HPV相关疾病时ICER为15,184€/QALY。
关键数值与推荐
- 基础案例ICER:24,763€/QALY(2018年欧元)。
- 纳入所有HPV相关疾病时ICER:15,184€/QALY。
- 覆盖率60%时ICER:40,401€/QALY。
- 结果对更高贴现率(6% vs 4%)和更短保护持续时间(20年 vs 终身)敏感。
临床怎么用
- 可为法国及类似国家将HPV疫苗接种规划从仅女孩扩展至性别中性提供卫生经济学依据。
- 决策时需考虑覆盖率水平及贴现率、保护持续时间等参数对成本效果的影响。
局限性
- 结果对更高贴现率(6% vs 4%)和更短保护持续时间(20年 vs 终身)敏感。
- 模型基于假设的覆盖率(26.2%或60%)及特定疾病范围,外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: In France, 9-valent HPV vaccination is recommended routinely for 11-14-years-old girls and as catch-up for 15-19-years-old girls. Recently, recommendation for gender-neutral vaccination (GNV) has been approved. The objectives of the study were to assess the public health impact and cost-effectiveness of a 9-valent GNV compared with girls-only vaccination program (GOV). METHODS: A published HPV disease transmission dynamic model accounting for herd protection effects with a 100-year time horizon was adapted and calibrated to French data. Epidemiological and economic outcomes included disease cases averted and quality-adjusted life years (QALY). Costs and incremental cost-effectiveness ratio (ICER) were measured in 2018 Euros (€). A coverage rate of 26.2% among girls and boys was assumed for the GNV program based on the current female coverage rate in France. The base case included genital warts, cervical, vulvar, vaginal, and anal cancers. Scenario analyses included all HPV-related diseases and considered higher vaccination coverage rate (60%). Deterministic sensitivity analyses on key inputs were performed. RESULTS: Over 100 years, GNV resulted in an additional reduction of 9,519 and 3,037 cervical cancer cases and deaths; 6,901 and 1,166 additional anal cancer cases and deaths; and a reduction of additional 1,284,077 genital warts compared with current GOV and an ICER of 24,763€/QALY. When including all HPV-related diseases, the ICER was 15,184€/QALY. At a higher coverage rate (60%), GNV would prevent 17,430 and 4,334 additional anogenital cancer cases and deaths and over two million genital warts compared with GOV with an ICER of 40,401€/QALY. Results were sensitive to a higher discount rate (6% versus 4%) and a shorter duration of protection (20 years versus lifetime). CONCLUSIONS: In France, GNV has a significant impact in terms of public health benefits and may be considered cost-effective compared with GOV at low and high coverage rates.
引用
- Majed L, Bresse X, El Mouaddin N, et al. Public health impact and cost-effectiveness of a nine-valent gender-neutral HPV vaccination program in France. Vaccine. 2020. PMID: 33261895. doi:10.1016/j.vaccine.2020.10.089
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。